1. Home
  2. HWH vs NXL Comparison

HWH vs NXL Comparison

Compare HWH & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.07

Market Cap

9.8M

Sector

Health Care

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.43

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
NXL
Founded
2021
2010
Country
United States
United States
Employees
N/A
7
Industry
Other Pharmaceuticals
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
8.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
HWH
NXL
Price
$1.07
$0.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
74.1K
322.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
47.37
N/A
EPS
N/A
N/A
Revenue
$866,926.00
N/A
Revenue This Year
N/A
$120.99
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.33
52 Week High
$7.77
$2.00

Technical Indicators

Market Signals
Indicator
HWH
NXL
Relative Strength Index (RSI) 41.70 51.70
Support Level $0.88 $0.37
Resistance Level $1.51 $0.46
Average True Range (ATR) 0.17 0.03
MACD -0.01 0.01
Stochastic Oscillator 20.00 81.88

Price Performance

Historical Comparison
HWH
NXL

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: